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Abstract
Background:  Discovery of tumor-selective antibodies or antibody fragments is a promising
approach for delivering therapeutic agents to antigen over-expressing cancers. Therefore it is
important to develop methods for the identification of target- and function specific antibodies for
effective drug delivery. Here we describe a highly selective and sensitive method for characterizing
the internalizing potential of multivalently displayed antibodies or ligands conjugated to liposomes
into tumor cells. The assay requires minute amounts of histidine-tagged ligand and relies on the
non-covalent coupling of these antibodies to fluorescent liposomes containing a metal ion-chelating
lipid. Following incubation of cells with antibody-conjugated liposomes, surface bound liposomes
are gently removed and the remaining internalized liposomes are quantitated based on
fluorescence in a high throughput manner. We have termed this methodology "Chelated Ligand
Internalization Assay", or CLIA.
Results: The specificity of the assay was demonstrated with different antibodies to the ErbB-2 and
EGF receptors. Antibody-uptake correlated with receptor expression levels in tumor cell lines with
a range of receptor expression. Furthermore, Ni-NTA liposomes containing doxorubicin were
used to screen for the ability of antibodies to confer target-specific cytotoxicity. Using an anti-
ErbB2 single chain Fv (scFv) (F5) antibody, cytotoxicity could be conferred to ErbB2-
overexpressing cells; however, a poly(ethylene glycol)-linked lipid (DSPE-PEG-NTA-Ni) was
necessary to allow for efficient loading of the drug and to reduce nonspecific drug leakage during
the course of the assay.
Conclusion: The CLIA method we describe here represents a rapid, sensitive and robust assay
for the identification and characterization of tumor-specific antibodies capable of high drug-delivery
efficiency when conjugated to liposomal nanocarriers.
Background
Antibodies and antibody fragments can deliver a variety of
agents, including drugs, genes, toxins or radioisotopes to
target cells expressing the appropriate receptor-antigen.
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Internalization of the antibody fragment to the interior of
the cell can in many cases increase the therapeutic effect of
the therapeutic agent [1,2]. A major advantage of receptor
mediated internalization as a drug delivery route is that
therapeutic agents can be delivered to target cells that spe-
cifically overexpress the receptor-antigen and thereby
increase efficacy while reducing systemic toxicity. For
example, anti-ErbB2 antibodies have been used to target
doxorubicin containing liposomes [3,4] or Pseudomonas
exotoxin (immunotoxin) into the interior of ErbB2 over-
expressing tumor cells [5,6]. A considerable fraction of
antibodies generated by immunization do not bind recep-
tors in a manner that triggers internalization [7,8]. Thus,
it is desirable to screen for antibodies that can elicit the
desired internalization response.
The most common method for monitoring internaliza-
tion of ligands and antibodies into cells involves radiola-
beling of the antibody, incubation of the labeled antibody
with the cells, and use of a low pH buffer (usually glycine-
HCl pH 2.8) to dissociate surface-bound antibody. How-
ever, reports from several laboratories indicate that this
buffer in some circumstances only partially dissociates
antigen-antibody complexes and therefore can introduce
considerable inaccuracies in internalization experiments
[9,10]. Alternatively, antibodies can be biotinylated with
NHS-SS-biotin and incubated with live cells. Following
specific reduction of biotin groups on cell surface bound
antibody with reducing agent, the antibody internaliza-
tion may be quantified by immunoblotting [11]. How-
ever, the accuracy of this method also relies on complete
removal of biotin from the cell surface bound antibody.
In addition, the stringent conditions that are required to
strip the cell surface in these procedures may affect cell
viability. Another limitation of these methods is that they
rely on laborious labeling of each candidate antibody,
allowing only a limited number of unique antibodies to
be screened for internalization. Finally, the direct labeling
of the antibody often results in loss of binding activity to
the antigen. These considerable limitations adversely
affect both the accuracy and throughput of presently avail-
able antibody selection methods and make it desirable to
develop a new and more efficient process for screening
internalizing antibodies. Here we report about a novel
assay for ligand or antibody internalization termed
"Chelated Ligand Internalization Assay" (CLIA), based on
a non-covalent attachment of (His)6-tagged ligands to a
detectable label bearing a dissociative bond, such as Ni-
NTA (nitriloacetic acid) chelation complex. The detecta-
ble label consisted of small unilamellar liposomes, thus
permitting internalization of multiple reporter molecules
in a single internalization event. The liposomes were for-
mulated with Ni-NTA-lipids capable of binding (His)6-
tagged proteins. The liposomes bearing Ni-NTA groups on
their surface were loaded with fluorescent dye and mixed
with a large pool of unique (His)6 containing anti-recep-
tor antibody fragments or intact antibody complexed to
(His)6-tagged Protein A.
Internalization of the ligand/liposome/receptor complex
was detected by fluorescence microscopy or fluorimetry
after gentle removal of cell surface bound complexes
using EDTA. Cellular uptake of the complex was depend-
ent on the specificity of the scFv as well as the ability of the
antibody fragment to trigger internalization, requiring <
50,000 receptors/cell for detection. The assay required
only small amounts (1 μg) of antibody fragment and
could be performed using crude, unpurified supernatants
of E coli that expressed the antibody fragment.
It is also important to translate the observed internaliza-
tion into cytotoxic readouts. To accomplish this, we used
Ni-NTA-conjugated antibody in combination with drug-
loaded liposomes to screen for target specific toxicity in
breast cancer cells.
Taken together, we describe a new and highly sensitive,
selective and robust method for the screening of large
arrays of antibodies (e.g. from a phage display library) for
specific internalizing ligands that can efficiently deliver
agents to selected, receptor-antigen overexpressing cell
types.
Results
Effect of (His)6-tagged internalizing ligands on the 
internalization of Ni-NTA liposomes into target cells
Liposomes were formulated with the entrapped
hydrophilic membrane-impermeable fluorescent marker
(HPTS) and various amounts of a Ni-NTA lipid (0.5, 2
and 5 % of phospholipid content). They were tested for
internalization into ErbB2- overexpressing SKBR3 tumor
cells via a highly internalizable anti-ErbB2 scFv antibody
(F5) [12] engineered to contain a C-terminal (His)6-tag
(anti-ErbB2-scFv-F5-(His)6). Following incubation of
SKBR3 cells with the liposomes and the antibody at 37°C,
the free and surface-bound liposomes were removed by
repeated rinsing with physiological buffer containing Ni-
chelating components (1 mM EDTA or 250 mM imida-
zole). Following a 4h incubation, cells were lysed in basic
solution and as a measure of internalization of liposomes
the HPTS fluorescence was read in a microfluorimeter. As
shown in fig. 1A, the absolute amounts of anti-ErbB2-
scFv-F5-(His)6-Ni-NTA-liposome constructs internalized
by SKBR3 cells increased with increasing liposome con-
centration, and with increasing Ni-NTA-lipids in the lipo-
some composition. The cellular uptake of the liposomes
was approximately linearly proportional to the concentra-
tion of liposomes in the reaction between 0–500 μM
phosholipid. Because disintegration or leakage of theBMC Immunology 2006, 7:24 http://www.biomedcentral.com/1471-2172/7/24
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entrapped marker would result in substantial reduction or
even disappearance of the fluorescent signal, these data
also indicate that the Ni-NTA-bearing liposomes were sta-
ble enough in the cell culture medium to serve as efficient
markers of internalization. Because the dye HPTS is highly
charged and highly water soluble it is trapped in the lipo-
some interior. The liposomes are also composed of a lipid
composition that does not disintegrate in the presence of
plasma (i.e. optimal PC:Cholesterol ratio) and thus the
marker would not be expected to be released extracellu-
larly.
The internalization of the liposomes was practically abol-
ished when the added antibody did not contain a (His)6-
tag (anti-ErbB2-scFv-F5), when the liposomes were for-
mulated without Ni-NTA-containing lipid (anti-ErbB2-
scFv-F5-(His)6 (no NTA)), when the (His)6-tagged anti-
body was omitted (Ni-NTA liposomes (no scFv)), or when
an irrelevant control scFv antibody (anti-VEGFR2-scFv-
4G7-(His)6) was used (fig. 1B). Thus, the mixing of an
internalizable, (His)6-tagged protein ligand with Ni-NTA-
bearing liposomes produced a non-covalent ligand-lipo-
some construct internalizable in a ligand-dependent man-
ner. Moreover, a non-covalent bond between a (His)6-
tagged ligand and a Ni-NTA chelating liposome was stable
enough to allow the internalization of the construct by lig-
and-reactive cells under the cell culture conditions.
To expand the utility of the assay to full-length antibodies
that do not originally contain a (His)6-tag, we prepared
an adapter molecule that could link the Ni-NTA lipo-
somes to the full-length antibodies. Therefore, the anti-
body binding reagent Protein A was conjugated to the
peptide CGGGHHHHHH (C = cysteine, G = glutamine, H
= histidine) using the bi-functional reagent sulfo-MBS
which cross links the thiol group in the peptide to primary
amines on Protein A. SDS-PAGE analysis confirmed suc-
cessful conjugation of multiple peptides per Protein A
molecule as demonstrated by an apparent shift in molec-
ular weight of approximately 10 kDa (results not shown).
When SKBR3 cells were co-incubated with Protein A-
(His)6 and the monoclonal anti-ErbB2 antibody Hercep-
tin (anti-ErbB2 mAb Herceptin) in the presence of fluores-
cently labeled Ni-NTA-liposomes, the liposomes were
specifically internalized as measured by fluorescence (fig.
1C). Protein A-(His)6 or Herceptin alone did not increase
the uptake of Ni-NTA-liposomes, indicating that it is
mediated by the Herceptin/Protein A-(His)6 complex (fig.
1C).
The internalized liposomes appear to localize to the endo-
somes as indicated by the apparent co-localization with
fluorescently labeled transferrin and little or no liposomes
remain at the cell surface following the EDTA or immida-
zole wash (fig. 1D). The liposome uptake is temperature
dependent and only little uptake is observed when the
liposomes are incubated at 4 C (fig. 1E).
Effect of the antibody concentration: improving the 
sensitivity of the assay
The sensitivity of the assay was tested by incubating
SKBR3 cells (naturally overexpressing ErbB2) with 500
μM of the HPTS-loaded liposomes containing 2% Ni-NTA
(of phospholipid content) and varying concentrations of
anti-ErbB2-scFv-F5-(His)6 (fig. 2A). Only increasing con-
centrations of the antibody resulted in the gradual
increase of the liposome internalization of the complex.
As expected, when the irrelevant anti-VEGFR2- scFv-4G7-
(His)6 control antibody (VEGFR2 is not expressed in sig-
nificant amounts on SKBR3 cells) was substituted for anti-
ErbB2-scFv-F5-(His)6 it did not mediate internalization
of the NTA-liposomes above the blank samples contain-
ing no antibody (fig. 2A). The detection limit of the assay
with the anti-ErbB2-scFv-F5-(His)6 on SKBR3 cells was
about 7 ug/ml.
In an attempt to increase the sensitivity of the assay, we
formulated Ni-NTA-liposomes with the following lipid
matrix composition: POPC, 25 molar parts; DOGS-NTA-
Ni, 5 molar parts; cholesterol, 20 molar parts; and
PEG(2000)-DSPE, 0.5 molar parts. Higher concentration
of DOGS-NTA-Ni (Ni-NTA = 20% of phospholipid con-
tent) was expected to increase the sensitivity, while inclu-
sion of a PEGylated lipid PEG-DSPE at low amount (1
mol.% of the total lipid) was to reduce liposome aggrega-
tion and potentially increase the non-specific cell-lipo-
some interactions due to increased Ni-NTA-lipid content.
These liposomes were similarly tested on ErbB2-overex-
pressing SKBR3 cells (about 106 receptors/cell) and on
MCF-7 cells with low ErbB2 expression (about 33-fold
less than SKBR3 cells; fig. 2B).
Following 4 hour incubation with the liposomes (0.5 mM
phospholipid) in the cell growth media in the presence of
0.1–10 μg/mL of anti-ErbB2-scFv-F5-(His)6, the cells were
washed 4 times with Mg2+- and Ca2+-containing Hanks'
BSS (to prevent cell detachment during washes). The
amounts of cell-associated liposomes were compared in
the samples after receiving two additional washes, either
with Mg2+- and Ca2+-free Hanks' BSS ("-EDTA"), or with
PBS containing 1 mM EDTA ("+EDTA"). The HPTS fluo-
rescence in alkaline lysates of the cells washed without
EDTA reflected the totality of cell-internalized and sur-
face-bound liposomes, while the fluorescence of the sam-
ples obtained after the EDTA wash was assumed to be
proportional to the internalized liposome fraction (fig.
2B).
In MCF-7 cells, the increasing amounts of anti-ErbB2-
scFv-F5-(His)6 to 10 μg/mL resulted in an approximatelyBMC Immunology 2006, 7:24 http://www.biomedcentral.com/1471-2172/7/24
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A. Effect of liposomal Ni-NTA-lipid concentration on target specific uptake into SKBR3 cells Figure 1
A. Effect of liposomal Ni-NTA-lipid concentration on target specific uptake into SKBR3 cells. Liposomes were formulated with 
entrapped 35 mM HPTS (fluorescent marker) and 0.5, 2 or 5 % Ni-NTA-lipid (% of phospholipid content) and tested for inter-
nalization into SKBR3 tumor cells using 20 μg/ml of anti-ErbB2-scFv-F5-(His)6. Liposomes and antibody were not pre-mixed 
but added sequencially to the media. Liposome concentration, μM liposome phospholipids; fluorescence, relative units. Fluo-
rescence represents a measure of internalization of anti-ErbB2-scFv-F5-(His)6 into SKBR3 cells. B. Specificity of the CLIA assay 
with respect to the presence of (His)6-tagged, internalizing ligand, and fluorescently labeled Ni-NTA-derivatized lipo-
somes.SKBR3 tumor cells were incubated with 500 μM Ni-NTA-liposomes (Ni-NTA = 5% of phospholipid content) and anti-
ErbB2-scFv-F5 (without a (His)6-tag), or an irrelevant control scFv antibody (anti-VEGRF2-scFv-4G7-(His)6) or liposomes 
without scFv (Ni-NTA liposomes (no scFv). Alternatively, anti-ErbB2-scFv-F5-(His)6 was co-incubated with liposomes formu-
lated without the Ni-NTA-DOGS lipid (anti-ErbB2-scFv- F5-(His)6 (no NTA)). All antibody concentrations were 20 μg/mL. 
The fluorescence was read as a measure of liposome internalization. C. Assaying internalization of monoclonal IgG antibodies 
without (His)6-tag by CLIA using a Protein A-(His)6 chemical conjugate. SKBR3 cells were incubated with anti-ErbB2-scFv-F5-
(His)6 (20 μg/mL), with anti-ErbB2 mAb Herceptin (20 μg/mL), Protein A-(His)6 alone (also 20 μg/mL), or mixture of anti-
ErbB2 mAb Herceptin and Protein A-(His)6 in the presence of 500 μM fluorescently labeled Ni-NTA-liposomes (Ni-NTA = 5% 
of phospholipid content). Immunoliposomes were allowed to internalize for four hours. The cells were lysed in base and the 
fluorescence was read as a measure of internalization. D. Co-localization of internalized liposomes with transferrin-PE. Ni-
NTA-liposomes, anti-ErbB2-scFv-F5-(His)6 (20 μg/mL), and transferrin-phycoerythrin were co-incubated for two hours with 
SKBR3 cells before observing cellular localization by fluorescence microscopy using a dual-pass filter. E. Temperature depend-
ence of liposome internalization. Ni-NTA liposomes (Ni-NTA = 5% of phospholipid content) were incubated in the presence 
or absence of ErbB2-scFv-F5-(His)6 (20 μg/mL) at either 4 C or at 37 C for 4 hours. The cells were then washed with either 
PBS or immidazole and lysed in base and the fluorescence was read as a measure of internalization.
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20% increase in the amount of cell-associated liposome
marker over the background (no antibody) control, which
was not statistically significant (p>011 by Student's t-test).
In SKBR3 cells, the amount of cell-associated liposomes
was still not significant at 0.1 μg/mL of anti-ErbB2-scFv-
F5-(His)6, but at both 1 μg/mL and 10 μg/mL of anti-
ErbB2-scFv-F5-(His)6, there was a statistically significant
(p < 0.03) increase of the liposome uptake by SKBR3 cells
to 150–200% over the background. The fluorescence ratio
between "+EDTA" and "-EDTA" samples indicated that
73–79% of the cell-associated liposome-antibody con-
structs were inaccessible to EDTA washing, i.e., internal-
ized. This value was in good agreement with the
previously determined degree of anti-ErbB2-scFv-F5-
(His)6 internalization into SKBR3 cells (about 80%)
using the traditional method of 125I-labeled antibody
and acid wash [13]. Thus, the improved liposome compo-
sition allowed an increase in the assay sensitivity to the
equivalent of about 1 μg/mL of a single chain Fv antibody.
CLIA does not require antibody purification
Because of the specific interaction of the (His)6-tag with
Ni-NTA on the liposome, we hypothesized that the assay
would permit the use of unpurified scFv recombinant
antibodies, even crude preparations such as bacterial
lysates, hybridoma media or ascites fluid, allowing a large
number of scFv antibody variants to be screened for inter-
nalization. To test this hypothesis, soluble scFv expression
was induced from E. coli in 96-well culture plates and the
supernatant tested for activity on live SKBR3 cells using
5% fluorescently labeled Ni-NTA liposomes. In previous
experiments (results not shown) we have determined that
SKBR3 cells tolerate as much as 50 % bacterial culture
supernatant for up to 24 h. Bacterial supernatants from
culture plates of E coli expressing the anti-ErbB2-scFv-F5-
(His)6 were mixed 1:3 (vol:vol) with cell culture media
containing 10 % serum, antibiotics, and 500 μM HPTS-
labeled Ni-NTA-liposomes (Ni-NTA = 5% of phospholi-
pid content). The mixture was subsequently incubated
with live SKBR3 cells. The amount of cell-internalized
liposomes -measured by fluorescence- was similar to
results obtained with 20 μg/mL of purified anti-ErbB2-
scFv-F5-(His)6 and exhibited similar specificity (results
not shown). Interestingly, the non-internalizing anti-
ErbB2-scFv-C6.5-(His)6 did not result in uptake of NTA
liposomes. This is consistent with previous results
A. Effect of the Ni-NTA liposome concentration in the CLIA assay Figure 2
A. Effect of the Ni-NTA liposome concentration in the CLIA assay. SKBR3 cells were co-incubated with (squares) or without 
(circles) 20 μg/mL of the anti-ErbB2-scFv-F5-(His)6 and varying concentrations of fluorescently labeled Ni-NTA-liposomes (Ni-
NTA = 2% of phospholipid content). Internalization of liposomes was measured in a microfluorimeter. B. Effect of antibody 
concentration in the CLIA assay. SKBR3 cells were coincubated with 500 μM of fluorescently labeled Ni-NTA-liposomes con-
taining 2 % of phospholipid content and varying concentrations of either the anti-ErbB2-scFv-F5-(His)6 (solid line-circles), or an 
irrelevant control antibody (anti-VEGRF2-scFv-4G7-(His)6)(squares), or with no antibody (dotted line – circles). C. Effect of 
the anti-ErbB2-scFv-F5-(His)6 concentration on the uptake of fluorescently labeled, minimally PEGylated Ni-NTA-liposomes 
(Ni-NTA = 5% of phospholipid content; 0.5 mol.% PEG(M.w. 2,000)-DSPE) by cells with high (SKBR-3 cells) or low (MCF-7 
cells) expression of ErbB2 receptor. (-EDTA), cells were washed with Hanks' BSS without EDTA; (+EDTA), cells were washed 
with Hanks' BSS + 1 mM EDTA. Experiments were done in duplicate. Error bars, SD. For all the experiments, immunolipo-
somes were allowed to internalize for four hours. The cells were lysed in base before reading the fluorescence in a microfluo-
rimeter. Incubation time was 4 hours.
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obtained by confocal microscopy analysis of the internal-
ization of anti-ErbB2-scFv-F5-(His)6 and anti-ErbB2-scFv-
C6.5-(His)6 [37]. For some antigens (e.g. some integrins),
multimerization is known to induce internalization; how-
ever, this data suggests that this is not the case with NTA
lipomes bound to ErbB2. A (His)6-tagged EGFR-specific
internalizable single chain Fv C10 (anti-EGFR-scFv-C10-
(His)6) [38] used as a control did not cause a noticeable
internalization of the liposomes over the blank sample
(antibody-free microbial supernatant, no scFv), consistent
with the low amount of EGF receptors expressed by
SKBR3 cells (fig. 3A).
Profiling tumor cell lines for antibody internalization
In addition to screening antibodies for internalization by
a given cell line, the assay allowed screening of cell lines
for their capacity to internalize a given antibody. As an
example, anti-EGFR-scFv-C10-(His)6 was used to profile a
panel of breast cancer cell lines and CHO transfectants
(fig. 3B). Only the cell line MD-MDA 468 and CHO cells
transfected with EGFR internalized significant amounts of
NTA-liposomes. The specificity of the assay is exemplified
by anti-EGFR-scFv-C10-(His)6 internalizing into CHO
cells transfected with EGFR, but not untransfected CHO
cells. Uptake of the fluorescent NTA liposomes into the
EGFR transfected CHO cells was 165 times that of
untransfected cells (fig. 3B).
The profile of anti-ErbB2-scFv-F5-(His)6 internalization
largely correlated with cell surface expression of ErbB2 as
determined by flow cytometry with anti-ErbB2-scFv-F5-
(His)6 (fig. 3C). However, the cell line SKOV3 did not
take up as many liposomes as would be expected from its
cell surface expression level of ErbB2. The poor internali-
zation of ErbB2 into this cell line has been described pre-
viously [4]. When total uptake into the same panel of cell
lines was determined using anti-ErbB2-scFv-F5-liposomes
(in which the antibody is covalently coupled to the lipid)
the discrepancy with anti-ErbB2-scFv-F5-(His)6 binding
determined by flow cytometry was less pronounced. Anti-
ErbB2-scFv-F5-(His)6 linked covalently to the liposome
surface is not removed by the EDTA washes used to dis-
rupt the chelation of (His)6-tagged scFv to Ni-NTA chelat-
ing liposomes. This is most likely due to cell surface
bound anti-ErbB2-scFv-F5-(His)6-liposomes. These
results suggest that the dissociating bond between the
detectable marker (a liposome) and the antibody is
required for an effective measurement of internalization.
Cytotoxicity of targeted liposomal therapeutics
Another potential application of the CLIA assay is the
screening and characterization of target-specific cytotoxic
activity of immunotargeted liposomal therapeutics. Since
different internalization pathways may lead to differences
in cytotoxicity of the immunoliposome the ability to rap-
idly test combinations of targeting molecules and drug-
loaded liposomes is of interest.
To test this application, we prepared fluorescently labeled
liposomes containing DOGS-NTA-Ni (Ni-NTA = 2% of
phospholipid content) and loaded them with the cyto-
toxic drugs vinorelbine, methotrexate, or doxorubicin.
Methotrexate was loaded passively and achieved a loading
efficiency of approximately 30 %, equivalent to liposomes
containing no DOGS-NTA-Ni (table 1). Doxorubicin and
vinorelbine were loaded at the drug/phospholipid ratio of
150 mg/mmol using an ammonium sulfate gradient-
based remote-loading method. This method typically
results in loading efficiencies of 95–100 % for these drugs
with neutral phospholipid liposomes. However, in the
presence of DOGS-NTA-Ni, the loading efficiency was
reduced to about 26.9% for doxorubicin and 9 % for
vinorelbine. We hypothesized that the reduced loading
resulted from an interaction of the amphipathic drugs
with the NTA-Ni functionality located at the membrane
surface. Unexpectedly, the high loading efficiency (92–
100%) was restored when a different NTA-Ni-lipid deriv-
ative, DSPE-PEG-NTA-Ni (NTA-Ni linked to the lipid
anchor via a PEG spacer), was substituted for DOGS-NTA-
Ni (fig. 4A). Liposomes with DSPE-PEG-NTA-Ni instead
of DOGS-NTA-Ni reached a loading efficiency of 92–100
%, similar to that seen with nonchelating liposomes.
These results suggest that extending the NTA-Ni chelating
group away from the membrane surface will be important
for forming liposomes where the drug is loaded via
remote-loading methodology, or where the drug either
transiently or permanently resides in the membrane.
Cytotoxicity studies with liposomal doxorubicin demon-
strate target specific activity for liposomes in the presence
of 20 μg/mL anti-ErbB2-scFv-F5-(His)6 (scFv-F5-NTA
liposomal DOX, fig. 4B). The cytotoxicity of DSPE-PEG-
NTA-Ni-liposomes containing doxorubicin (non-targeted
liposomal DOX, fig 4B, right panel) increased 26-fold in
SKBR3 cells, but not of liposomes prepared with DOGS-
NTA-Ni (non-targeted liposomal DOX, fig. 4B, left panel).
The difference in the IC50 between targeted and nontar-
geted liposomal doxorubicin in the PEG-linked construct
was 26-fold, 1.92 vs. 49.6 μg/mL, respectively. The IC50
for the free drug (free DOX) was 0.25 μg/ml (fig. 4B, right
panel). The cytotoxicity of doxorubicin-loaded DOGS-Ni-
NTA-containing liposomes did not change in the presence
of anti-ErbB2-scFv-F5-(His)6 (IC50 = 1.73 μg/mL in both
cases, fig. 4B, left panel) which likely reflects the higher
drug leakage rate from these liposomes, consistent with
their decreased drug-loading efficiency. Thus, accurate
screening of antibodies for target-specific activity using
liposomal drug constructs significantly benefited from
using a PEGylated lipid that may act as a spacer to move
the chelating group away from the membrane surface, atBMC Immunology 2006, 7:24 http://www.biomedcentral.com/1471-2172/7/24
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least when amphipathic drugs such as doxorubicin are
employed. The PEG spacer also provides the potential for
insertion of the chelating lipid into the outer monolayer
of drug-loaded or fluorescentlylabeled liposomes, thus
transforming a nontargeted liposome into a targeted one
upon addition of (His)6-containing scFvs.
A. Internalization of unpurified, bacterially produced antibodies into SKBR3 cells Figure 3
A. Internalization of unpurified, bacterially produced antibodies into SKBR3 cells. SKBR3 cells were co-incubated with superna-
tants of E. coli expressing anti-EGFR-scFv-C10-(His)6, the non-internalizing anti-ErbB2-scFv-C10-(His)6, anti-ErbB2-scFv-F5-
(His)6, or no scFv along with fluorescently labeled Ni-NTAliposomes (500 μM, Ni-NTA = 2% of phospholipid content). The 
fluorescence represents the amount of internalized antibody. B. Tumor cell profiling of EGFR with anti-EGFR-scFv-C10-(His)6 
and Ni-NTAliposomes. Anti-EGFR-scFv-C10-(His)6 was co-incubated with fluorescently labeled Ni-NTA-liposomes and cell 
lines expressing varying amounts of EGFR: SKBR3, SKOV3, BT474, MCF7, MD-MBA 453, MD-MDA 468, CHO-EGFR, or 
CHO. The fluorescence represents the uptake of labeled liposomes. The uptake of fluorescently labeled liposomes was nor-
malized to total cellular protein. C. Comparison of ErbB2 expression levels and uptake of anti-EGFR-scFv-F5-(His)6-conjugated 
immunoliposomes or anti-EGFR-scFv-F5-(His)6 chelated liposomes (anti-EGFR-scFv-F5-(His)6(+Ni-NTA-liposomes)). ErbB2 
expression levels on cells were determined using fluorescently labeled anti-EGFR-scFv-F5-(His)6 and flow cytometry (top 
panel). Alternatively, live tumor cells were incubated with anti-ErbB2-scFv-F5-(His)6 covalently coupled to fluorescently labeled 
liposomes (anti-ErbB2-scFv-F5-(His)6-conjugated liposomes) (middle panel). The CLIA assay was performed by co-incubation 
of anti-ErbB2-scFv-F5-(His)6 and fluorescently labeled Ni-NTA liposomes (bottom panel). Liposome fluorescence was read in a 
microfluorimeter. The fluorescence scale in all 3 panels is indicated as % of SKBR3 signal which was set to 100 %.
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Discussion
Antigen-specific antibody fragments can be directly
selected using phage display libraries where the fragments
are displayed on the surface of filamentous bacteri-
ophages [14]. These libraries can generate panels of
unique scFv antibodies with varying binding affinities to
virtually any antigen [15]. The selected antibody frag-
ments can be used for a wide variety of therapeutic appli-
cations, including directly altering normal antigen
function [16,17] and targeted delivery of radioisotopes,
toxins [20,21], small molecule drugs, liposomal drugs [2],
and direct effector cells to tumor sites [19]. The activity of
many of these immunotargeted therapies, including
immunotargeted nanocarriers for nucleic acids [12],
immunoliposomes [2], and immunotoxins [20], often
rely on intracellular delivery for optimal activity. Internal-
ization of the immunoliposomal drugs is thought to
result in intracellular release of the drug from the carrier,
a more uniform intratumoral distribution, and decreased
diffusion of the drug from the therapeutic targets
[24,27,28]. Thus, the preferential selection and character-
ization of internalizing ligands would aid in the develop-
ment of certain therapeutics that depend on
internalization for "activation" and thus optimal in vivo
efficacy.
A wide variety of methods have been described for select-
ing antigen-specific antibodies from phage display librar-
ies, most often related directly to antigen binding [14,29-
35]. Selection can be to antigen coated on plates, on col-
umn matrices, cells displaying the antigen, or to antigen
in solution followed by capture onto a solid support.
Alternatively, phage display libraries can be screened for
antibodies that elicit a particular response, such as inter-
nalization [36-38]. Using this method, a series of unique
and internalizing anti-ErbB2 [36,37] and anti-EGFR [38]
scFv antibodies have been identified and are currently
being utilized in our laboratories for the development of
targeted therapeutics [2,39] but the method is limited in
scope because it does not allow quantitation of internali-
zation nor does it characterize antibody internalization
into multiple cell lines.
Due to the increasing need for identification of internaliz-
ing ligands for therapeutic or diagnostic applications, the
development of sensitive and accurate methods for
screening or characterizing antibodies for internalizing
capabilities is essential. Current methods are filled with
inaccuracies, often due to incomplete removal of surface
bound ligand [9-11]. Other limitations involve loss of
binding activity upon ligand labeling, inefficient labeling,
or poor sensitivity.
Here we have described the development of a novel assay
that uses histidine-tagged antibody fragments bound to
Ni-NTA-lipid anchored liposomes encapsulating a mem-
brane impermeable fluorophore to monitor cellular inter-
nalization. We call this method "Chelated Ligand
Internalization Assay", or CLIA. The use of Ni2+-chelates
to bind (His)6-tagged proteins has been commonly
employed in the purification of recombinant proteins
[40]. Indeed, we often use this methodology for purifica-
tion of selected scFvs, to be used in different targeted ther-
apeutic and diagnostic applications. Chelating lipids,
most commonly lipid-modified derivatives of nitriol-
triacetic acid, have been used to study receptor-ligand
interactions in model membranes [41], for two-dimen-
sional crystallization of histidinetagged proteins [42], for
capturing modified peptides on membranes for western
blot analysis [43] or for reversible binding of proteins to
Table 1: Effect of Ni-NTA chelating lipids on the efficiency of loading for various anticancer drugs into liposomes.
Chelating lipid Drug loaded1 Drug-to-lipid2 ratio – input (μg/μmol) Drug-to-lipid3 ratio – final (μg/μmol) Loading4 efficiency (%)
none DOX 150 159.4 ± 6.1 106.3 ± 14.4
Ni-NTA-DOGS DOX 150 40.4 ± 4.3 26.9 ± 3.0
Ni-NTA-PEG-DSPE DOX 150 138.2 ± 10.2 92.2 ± 8.0
none VRB 150 150.2 ± 4.9 100.2 ± 3.4
Ni-NTA-DOGS VRB 150 13.6 ± 1.2 9.0 ± 0.9
Ni-NTA-PEG-DSPE VRB 150 149.6 ± 5.8 99.8 ± 4.0
none MTX 508 146.0 ± 20.3 28.7 ± 4.0
Ni-NTA-DOGS MTX 508 149.8 ± 6.6 29.5 ± 1.3
Ni-NTA-PEG-DSPE MTX 508 151.1 ± 7.2 29.7 ± 2.0
1Doxorubicin (DOX), vinorelbine (VRB), and methotrexate (MTX) were quantitated by absorbance at 498, 270, and 350 nm, respectively, following 
dissolution of the liposome sample in acid isopropanol.
2Phospholipid was determined by phosphate analysis as described by Bartlett, 1959
3Free drug was removed by Sephadex G-75 gel filtration chromatography.BMC Immunology 2006, 7:24 http://www.biomedcentral.com/1471-2172/7/24
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A. Chemical structures of DOGS-NTA-Ni and DSPE-PEG-NTA-Ni Figure 4
A. Chemical structures of DOGS-NTA-Ni and DSPE-PEG-NTA-Ni. DOGS-NTANi is an acidic lipid derivative with the func-
tional moiety located immediately at the membrane surface where it can potentially interact with amphipathic drugs, such as 
doxorubicin, that may be situated in or be transversing the membrane. DSPE-PEG-NTA-Ni, on the other hand, has the NTA-
Ni separated from the membrane by a poly(ethylene glycol) (PEG) spacer where interactions with drugs will likely be mini-
mized. Doxorubicin (DOX) is commonly carried in the liposomal lumen in a precipitated form. However, it must transverse 
the membrane in order to be actively loaded into the liposomes. Highly water soluble drugs, including methotrexate (MTX), 
are encapsulated passively and reside almost exclusively in the liposomal interior. B. Doxorubicin-dependent cytotoxicity of 
anti-ErbB2-scFv-F5-(His)6 coupled to different liposomes. In each of these graphs, free doxorubicin (▲) is compared to anti-
ErbB2-scFv-F5-(His)6-NTA-liposomal-DOX (●) and non-targeted NTAliposomal DOX with or without PEG spacer (❍). 
Cytotoxicity was determined using a calcein AM-cell viability assay as described in the methods section.
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membranes [44-46]. They have also been used in early
studies of potential therapeutic approaches, including
attaching costimulatory molecules to membrane vesicles
for tumor immunotherapy [47,48] or modification of
liposomes with various ligands such as an anti-HER2 pep-
tide [49].
Because internalization can be significantly affected by the
size and valency of ligand display for the internalizing
conjugate, the method described here can not be general-
ized to conjugates of widely variable sizes and/or degrees
of ligand display. The multivalent display of receptor lig-
ands or antibodies specific for cell-surface receptors can
dramatically increase avidity for its receptor compared to
the corresponding monovalent ligand [57], result in cross-
linking of cell surface receptors [73,59], and have an effect
on the efficiency of internalization into cells [23,72].
Indeed we have observed an increased internalization effi-
ciency when scFv are displayed multivalently on the sur-
face of phage [23]. However, conjugate binding and
internalization may also reach a plateau at a certain
valency and then decrease in efficiency at higher valencies
[68,2]. Finally, multivalent display of ligands can affect
the intracellular trafficking of the ligand or ligand-conju-
gate [63,58,71].
The size of the conjugate may also play a role in determin-
ing the efficiency of internalization. The optimum diame-
ter for spherical particles with respect to internalization
appears to be in the range of 50–60 nm [64,66,60]. How-
ever, particles up to 500 nm can be readily taken up into
nonphagocytic eukaryotic cells, with increasing size from
50–200 nm giving rise to a reduced efficiency of internal-
ization, and particles of higher size being taken up by a
distinct mechanism (i.e. caveolae) [74]. Ligand-targeted
liposomes are typically prepared in the optimum range of
80–120 nm due to the reduced clearance of small relative
to large particles in vivo, and the inherent instabilities
observed in drug encapsulation at very small sizes where
a high radius of curvature can result in increased mem-
brane permeability to encapsulated agents [65,67].
In this manuscript we describe a method for characteriz-
ing and screening multivalently displayed ligands using
scFv fragments conjugated noncovalently to the surface of
liposomes through a hexahistidine tag in the C-terminus
of the scFv. The liposomes have been designed to mini-
mize leakage or disassociation of the fluorescence probe
from the carrier. HPTS is a highly charged and water solu-
ble aqueous contents marker that is stably retained in the
liposomal interior [62] and has been widely utilized in
the liposome field to characterize the interactions of lipo-
somes with cells, specifically with respect to internaliza-
tion [70,62,4]. Great care must be chosen in the choice of
probe. Some lipid-soluble fluorescent dyes are readily
extractable by plasma proteins or cellular membranes
while some fluorescent aqueous contents markers (car-
boxyfluorescein) can rapidly leak from the liposome at
the low pH experienced during internalization due to pro-
tonation of the flurophores carboxyl groups [69,61].
Indeed, the later studies with encapsulated cytotoxic
agents illustrate this point, as doxorubicin encapsulated in
a less stable formulation gives rise to nonspecific cytotox-
icity (Figure 4).
The final studies in this manuscript describe a modifica-
tion of the initial CLIA method for characterizing the cyto-
toxicity of ligand-targeted immunoliposomal
therapeutics. Because the main purpose of the methodol-
ogy is to identify suitable therapeutic targeting molecules,
it is necessary to screen various targeting ligands for their
ability to elicit the desired effect. Although internalization
is generally known to be required for a substantial
improvement in antitumor activity, it is important to
understand that different targeting ligands and different
receptors may traffic to very different intracellular path-
ways thus resulting in differences in cytotoxic activity for
the delivered drug that depend on the targeting ligand
employed. We have recently observed in the same cell
line, cytotoxic activity that varied from 20–50 fold
between immunoliposomes prepared using two different
scFv targeting ligands, despite the fact that they resulted in
similar levels of internalized liposomes (data not shown).
Although it is possible to proceed directly to screening for
cytotoxicity, this screening is considerably more cumber-
some due to the fact that a series of dilutions is required
to accurately determine the MTD for the drug. It is thus
more desirable to reduce the number of scFv antibodies to
be screened for targeted cytotoxicity based on the results
of the more high throughput CLIA assay. However, in
order to accurately screen for differences in cytotoxic activ-
ity it was necessary to modify the liposome construct to
include a Ni2+ chelate that was sufficiently removed from
the surface of the carrier so as not to interfere with drug
encapsulation, or subsequent stability during the course
of the assay.
Conclusion
To our knowledge, this is the first study to use this cou-
pling methodology as a tool to quantitate receptor-medi-
ated internalization by taking advantage of the reversible
nature of the noncovalent Ni-(His)6 linkage. We have
found that (His)6-tagged scFvs bind to liposomes con-
taining these modified lipids and give sensitive reporting
of receptor-mediated internalization and target-specific
cytotoxic activity. In this work, we have also described the
synthesis of a new Ni-NTA-lipid chelate, DSPE-PEG-NTA-
Ni, containing a poly(ethylene glycol) linker for preparing
stable liposomal drug constructs with the capability of
rapidly binding his-tagged proteins. The low amount ofBMC Immunology 2006, 7:24 http://www.biomedcentral.com/1471-2172/7/24
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antibody required and the robust nature of the assay allow
for high throughput screening of internalizing ligands. In
addition, the application of this assay to cytotoxicity
assessments allows us to directly screen antibodies for the
target-specific activity that is often the ultimate goal of an
application for these molecules. We believe this technol-
ogy will prove invaluable for the rapid discovery and
development of targeting ligands against novel therapeu-
tic targets.
Methods
Materials
1-palmitoyl-2-oleoyl-phosphatidylcholine(POPC), dis-
tearoylphosphatidylcholine (DSPC), N- [methoxy(poly-
ethyleneglycol)-2000]-1,2-distearoyl-
phosphatidylethanolamine (PEG-DSPE), and 1,2-diole-
oyl-sn-glycero-3- [N(5-amino-1-carboxypentyl) imino-
diacetic aicd]succinyl] (nickel salt) (DOGS-NTA-Ni) were
purchased from Avanti Polar Lipids (Alabaster, AL). Cho-
lesterol was obtained from Calbiochem (San Diego, CA);
organic solvents, HPLC grade were from Fisher; Pitts-
burgh, PA; and other chemicals of reagent purity from
Sigma Chemicals; St. Louis, MO. Vinorelbine (Glaxo-
SmithKline; Triangle Park, NC), and doxorubicin (Bed-
ford Laboratories; Bedford, OH) were obtained
commercially from the pharmacy. Methotrexate was pur-
chased from Sigma Chemicals (St. Louis, MO). Pyranine,
or 8-hydroxypyrene-1,3,6-trisulfonic acid (HPTS), and
calcein-acetyoxymethyl ester (calcein-AM) were pur-
chased from Molecular Probes (Eugene, OR). Anti-
VEGFR-scFv-4G7-(His)6 was a kind gift from Udo
Geissler. Anti-ErbB2 mAb Herceptin was obtained form
the pharmacy.
Liposome preparation
Liposomes were prepared from POPC and cholesterol
(3:2 ratio), with varying amounts of chelating lipids
DOGS-NTA-Ni or DSPE-PEG-NTA-Ni (see below) and in
some cases also with a PEG lipid PEG-DSPE. (Avanti Lip-
ids; 0.5–5% of phospholipid content). The lipid compo-
nents were co-dissolved in chloroform, and the solution
was evaporated under reduced pressure to form a lipid
film. The lipid film was hydrated in an aqueous solution
containing 0–35 mM of the fluorescent marker HPTS
(Molecular Probes), adjusted to pH 7.0 with NaOH and
the osmolality of about 280 mOs mM/kg with NaCl. Fol-
lowing hydration, the liposomes were formed by mem-
brane extrusion 10–12 times through two stacked 0.1 μm
polycarbonate membranes (Corning) as described [4],
and unencapsulated HPTS was removed by gel-filtration
on a Sephadex 25 G-75 column using HEPES-buffered
saline (HBS; 20 mM HEPES, 144 mM NaCl. pH 7.2).
For encapsulation of the chemotherapy drugs doxoru-
bicin and vinorelbine, liposomes were formed in the pres-
ence of 250 mM ammonium sulfate and loaded using an
ammonium sulfate remote loading method [50,51].
Briefly, following extrusion of the lipid suspensions
through two stacked 0.1 μm polycarbonate filters, unen-
capsulated ammonium sulfate was removed on a Sepha-
dex G-75 column eluted with Mes-buffered saline (pH
5.5). The phospholipid content was then determined by
phosphate analysis [52] and either vinorelbine or dox-
orubin was added at a ratio of 150 μg drug/μmol phos-
pholipid. The drug was loaded by incubation with the
liposomes at 58°C for 45 min and subsequent quenching
of the reaction on ice for 15 min. Unencapsulated drug
was removed on a second Sephadex G-75 gel filtration
column. Loading efficiencies were typically in the range of
95–100 % when 150 μg drug per μmol phospholipid was
used. Methotrexate-loaded liposomes were prepared by
passive encapsulation in an aqueous solution containing
methotrexate (200 mM, 5 mM HEPES, pH 7.0). The
amount of drug in the purified liposome samples was
quantitated by absorbance (doxorubicin; OD498; vinore-
lbine, OD270; methotrexate, OD298) following dissolu-
tion of the drug-loaded liposomes in acid isopropanol
(90 % isopropanol, 10 % 1 N HCl), and phospholipid
content was determined by standard phosphate analysis
[52]. Drug loading efficiencies were calculated both in
absolute amounts where they are expressed as μg of drug/
μmol of phospholipids and in relative terms, where they
are expressed as the % of drug loaded relative to the initial
amount of drug added. The average liposome size was
determined by photon correlation spectroscopy, and was
typically in the range of 105–120 nm for liposomes pre-
pared under these conditions.
ScFv expression and purification
The scFv's C6.5 (anti-ErbB2) [53], and F5 (anti-ErbB2)
[37] were cloned into expression vector pUC119mycHis
[53] and expressed in E. coli TG1. Briefly, 0.75 L of media
(2xTY with 100 μg/mL ampicillin and 0.1% glucose) were
inoculated 1/100 with an overnight culture. The culture
was grown to an A600 of 0.9 and expression was induced
by the addition of isopropyl-b-D-thiogalactopyranoside
(IPTG) to a final concentration of 0.5 mM. The culture
was then incubated at 30°C for an additional four hours.
Cells were harvested by centrifugation (4000 × g, 20 min.)
and the pellets were resuspended in periplasmic extrac-
tion buffer (PPB) (30 mM Tris, 2 mM EDTA, 20% sucrose,
pH 8.0) containing DNase (100 μg/mL) and incubated on
ice for 30 min. The suspension was spun at 5000 × g for
20 min. The pellets were resuspended in osmotic shock
buffer (5 mM MgSO4) and incubated for another 20 min
on ice. The suspension was spun (7000 × g, 20 min.) and
supernatants from the PBB and MgSO4 fractions were
combined and cleared by centrifugation at 10000 rpm for
30 min at 4°C. The resulting solution was dialyzed in PBSBMC Immunology 2006, 7:24 http://www.biomedcentral.com/1471-2172/7/24
Page 12 of 15
(page number not for citation purposes)
(two changes, 4 L PBS, pH 8.0). All antibodies were puri-
fied by immobilized metal affinity chromatography
(IMAC) (Qiagen) followed by desalting on a PD10 col-
umn (Pharmacia). Protein concentrations were deter-
mined spectrophotometrically (absorbance at A280)
using the extinction coefficient ε = 1.4. For induction in
microtitre plates, wells containing 150 μl of 2 × TY con-
taining 100 μg/ml ampicillin and 0.1% glucose were inoc-
ulated with an overnight culture of TG1 with the plasmid
containing the scFv. Cultures were grown to an A600 ~ 1,
and scFv expression induced by the addition of IPTG to a
final concentration of 1 mM. Bacteria were grown over-
night at 30°C, centrifuged, and 30 μL of the supernatant
containing scFv used directly in the internalization assay.
Preparation of protein A-(His)6 conjugate
Protein A was conjugated to the (His)6-containing pep-
tide CGGGHHHHHH using the bifunctional reagent m-
maleimidobenzoyl-N-hydroxysulfosuccinimide ester
(Sulfo-MBS; Pierce). Protein A (2 mg) was treated with
Sulfo-MBS (0.2 mg) in PBS for one hour at room temper-
ature. Free Sulfo-MBS was removed by gel filtration chro-
matography and the protein then reacted with 0.2 mg of
the (His)6-containing peptide in phosphate buffered
saline (PBS) for one hour at room temperature. Free pep-
tide was removed by gel filtration chromatography.
CLIA assay procedure
Human breast cancer cells SKBR3, SKOV3, BT474, MCF7,
MDA-MB-453, MDA-MB-468 (American Type Culture
Collection) were grown to 80–90% confluence in the
media type recommended by ATCC supplemented with
10% fetal calf serum (FCS) and harvested by trypsiniza-
tion using standard techniques. Cells (10,000) were
seeded in 96-well plates and incubated overnight at 37°C.
The next day, Ni-NTA liposomes (0 – 1 mM total phos-
pholipid) were incubated for 4 h with the cells along with
the (His)6-containing ligand (20 μg/mL unless otherwise
indicated) in 100 μL tissue culture media supplemented
with 10 % FCS. Liposomes and antibody were not pre-
mixed but added sequencially to the cell culture media.
When supernatants of induced E. coli cultures were used
in the assay, 65 μL of cell culture media containing 10 %
serum and fluorescently labeled NTA-liposomes were
mixed with 35 μL of supernatants. To test the internaliza-
tion of monoclonal antibodies, which do not contain a
(His)6-tag, 10 μg/mL of Protein A-(His)6 was used to
complex 40 μg/mL of anti-ErbB2 mAB Herceptin. To strip
cell surface of non-internalized liposome/ligand com-
plexes, cells were washed 3–4 times with 170 μL PBS con-
taining 2 mM MgCl2, 2 mM CaCl2, and 1 mM EDTA or
with 250 mM phosphate buffered imidazole (pH 7.4),
causing dissociation of the (His)6-Ni-NTA bond in the
surface-bound liposome-ligand complexes. Cells were
then lysed in 0.01 M NaOH (50 μL) before the fluores-
cence was read in a FL600 microfluorimeter (BIOTEK)
using bandpass filters at 460/35 nm for excitation and
530/20 nm for emission. To quantify the amount of lipo-
somes internalized by the cells, the aliquots of HPTS-
loaded Ni-NTA liposomes containing known amounts of
liposome phospholipid were lysed, and the standard
curve of the marker fluorescence vs. liposome concentra-
tion was obtained in a similar manner. To study co-local-
ization with transferrin, Ni-NTA-liposomes, anti-ErbB2-
scFv-F5-(His)6 (20 μg/mL), and transferrin-phycoerythrin
(10 μg/mL; obtained from Molecular Probes) were co-
incubated for two hours with SKBR3 cells before observ-
ing cellular localization by fluorescence microscopy using
a dual-pass filter.
Quantification of surface bound anti-ErbB2-scFv-F5-(His)6 
by flow cytometry
Cells were harvested by trypsinization using standard
techniques. Anti-ErbB2-scFv-F5-(His)6 was incubated in
triplicate with 1 × 105 cells in 96-well plates with V shaped
wells for two hours at concentrations indicated. Cell stain-
ing with anti-ErbB2-scFv-F5-(His)6 was performed as
described elsewhere [54] and fluorescence was measured
by flow cytometry in using a FACSort cytofluorometer
(Becton-Dickinson) and median fluorescence (F) was cal-
culated using Cellquest software (Becton-Dickinson) and
the background fluorescence with cells only were sub-
tracted.
Synthesis of 6-(1,2-distearoyl-sn-glycerophosphoryl-
ethanolaminocarbonyl)-poly(oxyethylene)-
oxycarbonyl)amino-2-(N, N-bis-
carboxymethylamino)hexanoic acid nickel salt (DSPE-
PEG-NTA-Ni)
6-Amino-2-(N, N-bis-carboxymethylamino)-hexanoic
acid (N, N-biscarboxymethyl-L-lysine) was prepared as
previously described [44], except that the removal of CBZ
prospective group was in 4 M HBr/glacial acetic acid over-
night, resulting in the recovery of the product as a hydro-
bromide. Distearoylphosphatidylethanolaminocarbonyl-
poly(ethylene glycol)-propionic acid Nhydroxylsuccinim-
idyl ester (NHS-PEG-DSPE; 198 mg, 0.0445 mmol) pre-
pared from poly(ethylene glycol) (MW 3,400, Shearwater
Polymers, Huntsville, AL) was dissolved in the mixture of
anhydrous ethanol (1 ml) and anhydrous chloroform
(0.5 ml), mixed with a solution of 6-amino-2-(N, N-bis-
carboxymethylamino)hexanoic acid hydrobromide (40.8
mg, 0.120 mmol) in 0.5 ml of anhydrous ethanol and
0.15 ml of triethylamine (1.08 mmol), and stirred for 2 h
at 60°C. The reaction mixture was clarified by centrifuga-
tion at 15,500 × g for 5 min and clear supernatant was vac-
uum dried.and dissolved in 3 ml of 0.14 M NaCl. The
mixture was clarified by centrifugation at 15,500 × g for 5
min, and the clear supernatant was vacuum dried. The res-
idue was dissolved in 2.5 ml of 0.144 M NaCl, pH wasBMC Immunology 2006, 7:24 http://www.biomedcentral.com/1471-2172/7/24
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adjusted to 6.8 with 1 M NaOH, and 0.12 ml of 1 M
NiSO4 was added. The solution was applied to a 13 ml
chromatography column with cross-linked dextran beads
(Sephadex G-75, (Pharmacia Amersham, USA) using
0.144 M NaCl as eluent. The fractions appearing at the
void volume (total 4 ml) were collected, and lyophilized
overnight. The lyophilized cake was extracted with a mix-
ture of 2 ml anhydrous ethanol and 0.2 ml chloroform;
the insoluble matter was removed by centrifugation, and
the clear solution was vacuum dried. The residue was re-
dissolved in 2 ml of ethanol containing 0.1 ml chloro-
form, the solution clarified by centrifugation (15,500 × g,
5 min), and vacuum dried. Yield was 92 mg which repre-
sents 46 % of the theoretical yield. The product represent-
ing a bluish solid was soluble in a chloroform-methanol
mixture (60:40, vol:vol) and in water, giving light blue
solutions. The intended structure (fig. 4) was confirmed
by 1H-NMR.
Cytotoxicity studies
Specific cytotoxicity of ErbB2-targeted immunoliposomes
containing various anti-cancer drugs was evaluated in
SKBR3 cells plated at a density of 5,000 cells per well in
96-well plates and allowed to grow overnight. Immunoli-
posomes or control treatments were applied for 8 h at
37°C, followed by washing with PBS and re-adding
growth media. Cells were incubated for an additional
three days at 37°C and analyzed for cell viability using a
calcein-AM cytotoxicity assay [55,56]. Briefly, following
the three-day incubation, the media was removed and the
cells washed once with 200 μl of phosphate buffered
saline (PBS). Subsequently, PBS (100 μl) was added to
each well and mixed gently with 100 μl of a freshly pre-
pared calcein-AM stock (1 μM) in PBS. The cells were then
allowed to incubate for 45 min at 37°C in a CO2 incuba-
tor. Following the incubation period, the cells were
washed once with PBS (100 μl). A final volume (200 μl)
of PBS was added to the cells and the amount of calcein
produced by the cells was analyzed by measuring the flu-
orescence in a BioTek (FL600) fluorescence microtiter
plate reader using 485/35 and 530/20 nm bandpass filters
for excitation and emission, respectively. The amount of
calcein fluorescence was normalized to that of non-
treated cells and expressed as % cell viability.
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